[Spring, Health Guardian] Korea's First Clinical Phase 3 Trial of 'Squeezable Antipyretic' for Infants and Young Children

Hanmi Pharm, 'Maxibu Kids Syrup'

[Asia Economy Reporter Kim Heung-soon] Hanmi Pharmaceutical has newly launched MaxiBufen Syrup for infants and young children in a "squeeze pouch" form. This product has proven its efficacy and safety through the first domestic Phase 3 clinical trial targeting infants and young children. Additionally, by enhancing portability and reducing the inconvenience of having to measure a specific dose each time, it is expected to be a great help to parents raising children.

The official product name of the squeeze pouch MaxiBufen is MaxiBuKids Syrup. It contains "dexibuprofen," the active ingredient separated from ibuprofen, which is the fever-reducing component. Dexibuprofen produces the same effect as ibuprofen with a smaller dose. Separating only the active ingredient reduces side effects and further increases safety. Its grape flavor makes it easy for children who are reluctant to take medicine to consume.

MaxiBuKids Syrup comes in 6㎖ single-dose stick packs, with 10 sticks per box. It can be taken by squeezing one stick at a time. The dosage can be adjusted according to age or weight. Because it is individually stick-packed, it can be taken quickly and conveniently even when going out or in emergency situations.

A Hanmi Pharmaceutical official said, "MaxiBufen is a product with proven fast efficacy and safety to the extent that it has become a household essential medicine for families raising children," adding, "While the existing MaxiBufen Syrup is for home use, the newly launched MaxiBuKids Syrup is expected to be useful when going out or in emergencies."

This content was produced with the assistance of AI translation services.